Why it matters
The findings could matter to people with relapsing MS and the U.S. health-care system if remibrutinib becomes an available treatment option. The article does not provide enough detail to assess the size of the benefit or its costs.
RESEARCH & TREATMENTS • UNITED STATES
Remibrutinib reduced MS relapses versus teriflunomide in Phase III trials
This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
This event has left the current brief. The summary below describes the stored record; open the original sources for current conditions.
BLUF
A MedPage Today report says twice-daily remibrutinib reduced relapses more than teriflunomide in patients with relapsing multiple sclerosis in two Phase III trials. The report does not provide effect sizes or say whether the drug has been approved.
HOW THIS BRIEF WAS MADE 1 outlet: 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections